Amisulpride
- Generic Name
- Amisulpride
- Brand Names
- Barhemsys
- Drug Type
- Small Molecule
- Chemical Formula
- C17H27N3O4S
- CAS Number
- 71675-85-9
- Unique Ingredient Identifier
- 8110R61I4U
- Background
Amisulpride is a benzamide derivative and a dopamine receptor antagonist that selectively works on dopamine D2 and D3 receptors. As an antipsychotic agent, amisulpride alleviates both positive and negative symptoms of schizophrenia, and it exhibits antidepressant properties in patients with psychiatric disorders, dysthymia, and major depression. Amisulpride ...
- Indication
Intravenous amisulpride is indicated in adults for the prevention of postoperative nausea and vomiting, either alone or in combination with an antiemetic of a different class. It is also indicated for the treatment of postoperative nausea and vomiting in patients who have received anti-emetic prophylaxis with an agent of a different class or have not receive...
- Associated Conditions
- Acute Schizophrenia, Chronic Schizophrenia, Negative Symptoms, Post Operative Nausea and Vomiting (PONV)
- Associated Therapies
- -
A Comparison of the Efficacy of Amisulpride and Placebo in the Prevention of PONV in Patients at Moderate-to-high Risk of PONV.
- First Posted Date
- 2023-04-21
- Last Posted Date
- 2023-04-21
- Lead Sponsor
- Qilu Pharmaceutical (Hainan) Co., Ltd.
- Target Recruit Count
- 516
- Registration Number
- NCT05822713
Post Operative Nausea and Vomiting (PONV) Rescue Outcomes After Amisulpride Treatment
- First Posted Date
- 2021-07-08
- Last Posted Date
- 2023-04-07
- Lead Sponsor
- Acacia Pharma Ltd
- Registration Number
- NCT04954365
Low Dose Amisulpride Vs Olanzapine-Fluoxetine Combination in Post-Schizophrenic Depression
- Conditions
- Interventions
- First Posted Date
- 2021-05-06
- Last Posted Date
- 2021-06-03
- Target Recruit Count
- 60
- Registration Number
- NCT04876521
- Locations
- 🇮🇳
All India Institute of Medical Sciences, Bhubaneswar, Orissa, India
Study on the Gut Microbial Mechanism of Negative Symptoms of Schizophrenia
- Conditions
- Interventions
- First Posted Date
- 2020-09-01
- Last Posted Date
- 2020-09-01
- Lead Sponsor
- Shanghai Mental Health Center
- Target Recruit Count
- 6
- Registration Number
- NCT04533724
Atypical Antipsychotics Influence on the Safety of the Heart and Monitoring Indicators Model Building
- Conditions
- Interventions
- First Posted Date
- 2020-06-24
- Last Posted Date
- 2020-08-26
- Lead Sponsor
- Shanghai Mental Health Center
- Target Recruit Count
- 350
- Registration Number
- NCT04446234
- Locations
- 🇨🇳
CHINA, Shanghai, Minhang, China
Amisulpride Treatment for BPSD in AD Patients
- Conditions
- Interventions
- First Posted Date
- 2020-04-10
- Last Posted Date
- 2022-11-16
- Lead Sponsor
- Tianjin Anding Hospital
- Target Recruit Count
- 76
- Registration Number
- NCT04341467
- Locations
- 🇨🇳
Tianjin Anding Hospital, Tianjin, Tianjin, China
Dopamine Receptor Contributions to Prediction Error and Reversal Learning in Anorexia Nervosa
- Conditions
- Interventions
- First Posted Date
- 2019-10-16
- Last Posted Date
- 2024-10-08
- Lead Sponsor
- University of California, San Diego
- Target Recruit Count
- 31
- Registration Number
- NCT04128683
- Locations
- 🇺🇸
University of California San Diego, San Diego, California, United States
Clinical Evaluation of Acupuncture Treatment for Negative Symptoms of Schizophrenia
- First Posted Date
- 2019-01-14
- Last Posted Date
- 2019-01-14
- Lead Sponsor
- Shanghai Mental Health Center
- Target Recruit Count
- 50
- Registration Number
- NCT03802838
- Locations
- 🇨🇳
Shanghai Mental Health Center, Shanghai, Shanghai, China
Chinese First Episode Schizophrenia's Optimal Dynamic Antipsychotic Treatment Regime
- First Posted Date
- 2018-04-27
- Last Posted Date
- 2018-08-01
- Lead Sponsor
- Shanghai Mental Health Center
- Target Recruit Count
- 1260
- Registration Number
- NCT03510325
- Locations
- 🇨🇳
Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine, Shanghai, Shanghai, China
Dopamine and Opioid Receptor Antagonists Reduce Cue-induced Reward Responding and Reward Impulsivity
- Conditions
- Interventions
- First Posted Date
- 2015-09-23
- Last Posted Date
- 2015-09-23
- Lead Sponsor
- University of Zurich
- Target Recruit Count
- 121
- Registration Number
- NCT02557984
- Locations
- 🇨🇭
University Hospital, Zurich, Switzerland
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.